---
schema_version: "secwatch.filing_event.v1"
accession: "0001459839-24-000039"
form_type: "8-K"
ticker: "SIBN"
cik: "0001459839"
company_name: "SI-BONE, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:55:21.970770+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SI-BONE reports Q1 revenue $37.9M (+16% YoY); raises FY2024 guidance to $164-166M

## Summary
- Worldwide revenue $37.9M, up 16% YoY; U.S. revenue $35.4M, also up 16%.
- Gross margin ~79%, down from ~82% due to product and procedure mix.
- Net loss $10.9M ($0.27 diluted EPS) vs $11.1M ($0.32) in Q1 2023; adjusted EBITDA loss $4.0M.
- FY2024 revenue guidance raised to $164-166M (18-20% growth) from $162-165M.
- Surpassed 100,000 procedures; introduced smaller diameter iFuse Bedrock Granite implant.

## SEC filing metadata
- accession: 0001459839-24-000039
- form_type: 8-K
- ticker: SIBN
- cik: 0001459839
- company_name: SI-BONE, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1459839/000145983924000039/0001459839-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1459839/000145983924000039/sibn-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001459839-24-000039
- JSON: https://secwatch.observer/filing/0001459839-24-000039.json
- Plain text: https://secwatch.observer/filing/0001459839-24-000039.txt

## Key facts
- Earnings Releases
  SI-BONE, Inc. reported the quarter ended March 31, 2024 results: revenue $37.9 million, net income $10.9 million, or $0.27 per diluted share. Guidance raised.
  - Period: the quarter ended March 31, 2024
  - Revenue: $37.9 million
  - Net income: $10.9 million, or $0.27 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) • Worldwide revenue of $37.9 million, representing growth of ~16% • U.S. revenue of $35.4 million, representing growth of ~16% • Gross margin of ~79% • Over 1,100 U.S. active physicians, representing an increase of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1459839/000145983924000039/0001459839-24-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.